MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?

Core Viewpoint - MediWound (MDWD) shares experienced an 8.5% increase, attributed to positive investor sentiment regarding the company's product pipeline and upcoming sales expectations [1][2]. Company Overview - MediWound is developing EscharEx, currently in mid to late-stage studies for treating various ulcer indications, with a regulatory filing for venous leg ulcers expected in 2025 [2]. - Another candidate, MW005, is in mid-stage development for non-melanoma skin cancer [2]. - The company markets NexoBrid, approved for eschar removal in patients with thermal burns, and is expected to see year-over-year sales growth in the upcoming quarterly release [2]. Financial Expectations - The company is projected to report a quarterly loss of $0.61 per share, reflecting a year-over-year change of -221.1$5.8 million, representing an 8.6% increase from the same quarter last year [3]. - The consensus EPS estimate has been revised 0.6% lower over the last 30 days, indicating a negative trend in earnings estimate revisions [4]. Industry Context - MediWound is part of the Zacks Medical - Drugs industry, which includes other companies like Nektar Therapeutics (NKTR) [4]. - Nektar's consensus EPS estimate has changed by +0.2% over the past month, with a year-over-year change of +40.9% [5].